Gemmus Pharma Closes on Series A Funding to Develop Superior Flu Drug  
6/28/2012 9:45:28 AM

SAN FRANCISCO--(BUSINESS WIRE)--Gemmus Pharma Inc. announced today that it has closed on a Series A funding. Gemmus is a privately held biotechnology company developing an improved host-targeted treatment for influenza. The funding will be used to prepare for an IND filing of a candidate therapy that reduces symptoms during influenza infections by modulating the body’s own beneficial immune response. The company has recently secured IP around its novel technology for drug development (“EP2 and EP4 agonists as agents for the Treatment of Influenza A viral infections”, US patent 8,183,286).